Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Operating Leases (2019 - 2025)

Neurogene's Operating Leases history spans 5 years, with the latest figure at $6.8 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 27.45% year-over-year to $6.8 million; the TTM value through Dec 2025 reached $6.8 million, down 27.45%, while the annual FY2025 figure was $6.8 million, 27.45% down from the prior year.
  • Operating Leases reached $6.8 million in Q4 2025 per NGNE's latest filing, down from $7.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $14.9 million in Q4 2023 to a low of $6.8 million in Q4 2025.
  • Average Operating Leases over 3 years is $9.7 million, with a median of $9.5 million recorded in 2023.
  • The largest YoY upside for Operating Leases was 17.12% in 2024 against a maximum downside of 36.73% in 2024.
  • A 3-year view of Operating Leases shows it stood at $14.9 million in 2023, then tumbled by 36.73% to $9.4 million in 2024, then dropped by 27.45% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Operating Leases are $6.8 million (Q4 2025), $7.1 million (Q3 2025), and $7.8 million (Q2 2025).